Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's informed the exchanges that the USFDA completed a Good Manufacturing Practice (GMP) inspection at its API manufacturing facility in Middleburgh, New York, from May 12 to May 16, 2025. The inspection ended with the company being issued a Form 483 containing 2 observations. The company stated it will address these observations within the timeline required by the USFDA. A Form 483 is a standard document issued by the FDA when inspectors note conditions that may not fully comply with regulations.
A Form 483 with only 2 observations is generally considered minor and is part of routine regulatory interactions. Short-term stock impact is likely limited, though investors will watch for whether the company resolves the observations on time or if the matter escalates into a Warning Letter.